Immutep Competitors and Similar CompaniesClear all
Immutep's competitors and similar companies include OncoTherapy Science, Numab, Day One Biopharmaceuticals and Acrivon.
 Immutep Immutep (formerly Prima BioMed) is a biotechnology company focused on developing autoimmune and cancer immunotherapy treatment. |  OncoTherapy Science OncoTherapy Science is a company engaged in research and development of cancer therapeutics. |  Day One Biopharmaceuticals Day One Biopharmaceuticals is a company that develops drugs and therapies intended to find a cure for cancer. |  Acrivon Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline. | ||
Founding Date | Founding Date 2001 | Founding Date 2001 | Founding Date 2011 | Founding Date 2018 | Founding Date 2018 |
Type | Type Public | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Sydney, AU HQ Sydney, AU The Rocks, AU Orsay, FR Berlin, DE Leipzig, DE | Locations Kawasaki, JP HQ | Locations Wädenswil, CH HQ | Locations South San Francisco, US HQ | Locations Watertown, US HQ Lund, SE |
Employees | Employees 2427% decrease | Employees 54 | Employees 681% decrease | Employees 20 | Employees 415% increase |
Valuation ($) | Valuation ($) 282.4 m | Valuation ($) 56.9 m | Valuation ($) N/A | Valuation ($) 1.4 b | Valuation ($) 256.1 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ¥808.5m (FY, 2026) | Revenue (est.) N/A | Revenue (est.) $158.2m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods ¥794.6m (FY, 2026) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $5m (FY, 2025) | Gross profit ¥14m (FY, 2026) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income ($61.4m) (FY, 2025) | Net income (¥910.6m) (FY, 2026) | Net income N/A | Net income ($107.3m) (FY, 2025) | Net income ($77.9m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 132.3m | Total funding raised $ 60m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
OncoTherapy Science
HQ
Kawasaki, JP
Employees
54
OncoTherapy Science is a company engaged in research and development of cancer therapeutics.
View company
Numab
HQ
Wädenswil, CH
Employees
68↓ 1% decrease
Numab Therapeutics is an oncology-focused biopharmaceutical company.
View companyDay One Biopharmaceuticals
HQ
South San Francisco, US
Employees
20
Day One Biopharmaceuticals is a company that develops drugs and therapies intended to find a cure for cancer.
View companyAcrivon
HQ
Watertown, US
Employees
41↑ 5% increase
Acrivon (also known as Acrivon Therapeutics) is a clinical-stage oncology company that leverages a precision medicine platform called Acrivon Predictive Precision Proteomics (AP3) for the development of a drug pipeline.
View company